With the newly completed OT-101 and IL-2 Phase 1 trial, Oncotelic is poised to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung ...

BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical ...

A number of Premier League clubs have an eye on Tyler Dibling, but they face a battle. Tottenham Hotspur and Manchester City might have the Southampton starlet in their sights, but the teenager ...

1Cancer Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts.